Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract

Impact · against what's priced in

Zentalis Pharmaceuticals' publication of overall survival (OS) data for azenosertib provides a material update on its lead candidate in ovarian cancer. As a late-stage clinical data release for a first-in-class inhibitor, this provides a concrete catalyst for valuation based on clinical efficacy.

ZNTL+0.60

No priced-in read yet